Business Development

Partnerships

Autonomous University of Barcelona

Ability Pharmaceuticals has a research collaboration with Dr. José Miguel Lizcano's laboratory at the Department of Biochemisty, Faculty of Medicine of the Autonomous University of Barcelona, in Bellaterra.

Vall d'Hebron Institut d’Oncologia

Ability Pharmaceuticals Phase II clinical studies performed at the Department of Oncology at the Vall d'Hebron University Hospital. Dr. Ana Oaknin is the Principal Investigator.

SciClone Pharmaceuticals, Inc.

In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M

IDIBAPS

Ability Pharmaceuticals has research collaborations with the Area of Molecular and Translational Oncology of the IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), associated with the Hospital Clinic de Barcelona and the University of Barcelona. The Area is led by Dr. Pere Gascon.

Hospital Clínic de Barcelona

Ability Pharmaceuticals conducted the Phase I/Ib clinical trials at the Medical Oncology Service and at the Clinical Institute of Hemato-Oncological Diseases y (ICMHO) of the Hospital Clinic de Barcelona. Dr. Laura Vidal was the Principal Investigator.

Institut Catala d'Oncologia

Ability Pharmaceuticals perform the phase II clinical studies in the Catalan Institute of Oncology (ICO) in the centers of L'Hospitalet, Girona and Badalona. Dr. Ernest Nadal, Dr. Joaquim Bosch and Dr. Teresa Moran are the principal investigators, respectively.

University of Girona


Ability Pharmaceuticals has a research collaboration with Dr. Teresa Puig's laboratory at the Department of Molecular Oncology, Faculty of Medicine of the University of Girona (Catalonia).

Universitat de Lleida

Ability Pharmaceuticals has a research collaboration with Dr. Xavier Matias-Guiu, head of pathological anatomy at Bellivtge Hosptial and Arnau de Vilanova Hospital and director of Biomedical Research Institute of Lleida (IRB). The collaboration also includes Dra. Nuria Eritja, head of the pathological laboratory and oncology group at IRB, and Dra. Eva Colàs, principal investigator currently in Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Vall d'Hebron Research Institute


Ability Pharmaceuticals has a research collaboration with Dr. Miguel Segura's laboratory of the Tranlational Research in Pediatric Carcer Group of the Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Medalchemy

Medalchemy has developed the synthetic routes of the drug candidates being developed by Ability Pharmaceuticals and is proceeding to the escalation of their production.
 
Medalchemy is base at the Science Park of the University of Alicante/Alacant.
 

European Network for the Study of Cholangiocarcinoma

We belong to the ENS-CCA, a group of active researchers with a broad interest in cholangiocarcinoma clinical area, which has significantly contributed to the study into the pathophysiology of the biliary tree and development/onset of cholangiocarcinoma, and pursuing basic, translational and clinical research in an effort to identify treatment options with successful outcome for this type of cancer. 

LATEST NEWS

07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG